Background: Nonmelanoma skin cancer is the most common form of cancer in humans and also the malignant disease that is increasingly common among kidney transplant recipients.
Objective: To determine the epidemiological characteristics of renal transplant recipients with nonmelanoma skin cancer seen at a referral transplantation center.
Methods: Cross-sectional descriptive study with renal transplant recipients presenting nonmelanoma skin cancer, treated at a transplantation referral center between 08/01/2004 and 08/31/2009. Analyzed variables were: gender, age, skin phototype, occupational and recreational sun exposure, use of photoprotection, personal and family history of non-melanoma skin cancer, clinical type and location, time between transplantation and the appearance of the first nonmelanoma skin cancer, occurrence of viral warts, timing of transplantation, type of donor, cause of kidney failure, previous transplants, comorbidities, pre-transplant dialysis, type and duration of dialysis.
Results: 64 subjects were included. Males--71.9%; low skin phototypes (up to Fitzpatrick III)--89%; mean age--57.0 years--and mean age at transplant--47.3 years; sun exposure--67.2% occupational--and 64.1% recreational; photoprotection--78.2% (although only 34.4% in a regular manner); squamous cell carcinoma--67.2%; squamous cell carcinoma/basal cell carcinoma ratio--2:1; personal history of nonmelanoma skin cancer--25%--and family history--10.9%; location at photoexposed area--98.4%; average latency time between transplantation and first nonmelanoma skin cancer appearance--78.3 months; viral warts (HPV) after transplant--53.1%; average timing of transplantation--115.5 months; living donor--64.1%; triple regimen (antirejection)--73.2%; comorbidities--92.2%; pre-transplant dialysis--98.4%; hemodialysis--71.7%; average duration of dialysis--39.1 months; previous transplants--3.1%; hypertension as cause of renal failure--46.9%.
Conclusion: This study allowed the epidemiological characterization of a population of kidney transplant recipients with nonmelanoma skin cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155952 | PMC |
| http://dx.doi.org/10.1590/abd1806-4841.20142590 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of the microbiome in skin cancer development and treatment.
Curr Opin Oncol
January 2025
San Roque Hospital, Lanzarote, Spain.
Purpose Of Review: Recent research underscores the significant influence of the skin and gut microbiota on melanoma and nonmelanoma skin cancer (NMSC) development and treatment outcomes. This review aims to synthesize current findings on how microbiota modulates immune responses, particularly enhancing the efficacy of immunotherapies such as immune checkpoint inhibitors (ICIs).
Recent Findings: The microbiota's impact on skin cancer is multifaceted, involving immune modulation, inflammation, and metabolic interactions.
We examined the risk of subsequent malignant neoplasms (SMNs) in 1720 patients with hematologic cancers given allogeneic hematopoietic grafts from 03/1998 to 08/2023 after nonmyeloablative conditioning regimens. With a median follow-up of 12 years, the cumulative incidence of SMNs was 17% (95% CI, [15%, 19%]). Most SMNs (n = 543) were non-melanoma skin cancers seen in 208 patients; unfortunately, information on these cancers was not available in the Surveillance, Epidemiology, and End Results (SEER) database for comparison with such tumors in the general population.
View Article and Find Full Text PDFIs there an association of blood cadmium level with nonmelanoma skin cancer: results from a cross-sectional study.
Front Public Health
January 2025
Department of Burn and Plastic Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Objective: Nonmelanoma skin cancer (NMSC) is a common malignancy that starts in the top layer of the skin. Exposure to heavy metals has been suggested to increase the risk of skin cancer. Cadmium, prevalent in various industries and present in cigarette smoke, has been implicated in potential skin effects in animal studies.
View Article and Find Full Text PDFCorrigendum to "Artificial intelligence-driven hydrogel microneedle patches integrating 5-fluorouracil inclusion complex-loaded flexible pegylated liposomes for enhanced non-melanoma skin cancer treatment" [Int. J. Pharm. 669 (2025) 125072].
Int J Pharm
January 2025
Pharmaceutical Development of Green Innovations Group (PDGIG) Department of Industrial Pharmacy Faculty of Pharmacy Silpakorn University Nakhon Pathom Thailand; Research and Innovation Center for Advanced Therapy Medicinal Products, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000 Thailand. Electronic address:
Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol.
BMJ Open
January 2025
Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
Introduction: Long-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer outcomes among individuals with multiple sclerosis (MS) treated with fingolimod. This study aims to describe a protocol for investigating the relationship between fingolimod use and the incidence of skin cancer among individuals with MS.
Methods And Analysis: We will use population-based administrative health data from two Canadian provinces (British Columbia and Alberta) to conduct an observational cohort 'trial emulation' study with an active comparator and new-user design.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!